PriceTargets.com logo

Accendra Health - ACH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.17
  • Forecasted Upside: 76.94%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.92 As of 05/26/2026 11:20 AM ET
▲ +0.09 (3.18%)

This chart shows the closing price for ACH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Accendra Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACH

Analyst Price Target is $5.17
▲ +76.94% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Accendra Health in the last 3 months. The average price target is $5.17, with a high forecast of $6.00 and a low forecast of $4.50. The average price target represents a 76.94% upside from the last price of $2.92.

This chart shows the closing price for ACH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Accendra Health. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/26/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/26/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/12/2026UBS GroupBoost TargetNeutral ➝ Neutral$3.00 ➝ $4.50
5/12/2026CitigroupBoost TargetBuy ➝ Buy$3.25 ➝ $5.00
5/12/2026Robert W. BairdBoost TargetOutperform ➝ Outperform$5.00 ➝ $6.00
4/21/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
4/8/2026Weiss RatingsInitiated CoverageSell (E+)
(Data available from 5/26/2021 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2026
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/26/2026

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Accendra Health

Accendra Health Inc is a nationwide provider of products, technology, and services that support health beyond the hospital by connecting patients, providers, and insurers. Through its brands, Apria and Byram Healthcare, the company delivers disposable medical supplies, integrated home healthcare equipment, and related services that help improve health outcomes and quality of life for individuals with chronic, complex, and acute health conditions. Its offerings span diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment, along with patient support services. The company also supplies a broad range of home medical equipment and patient care products, including ostomy, wound care, urology, and incontinence solutions.
Read More

Today's Range

Now: $2.92
Low: $2.82
High: $3.13

50 Day Range

MA: N/A

52 Week Range

Now: $2.92
Low: $1.84
High: $9.55

Volume

128,267 shs

Average Volume

1,054,420 shs

Market Capitalization

$223.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Accendra Health?

The following Wall Street sell-side analysts have issued stock ratings on Accendra Health in the last year: Citigroup Inc., Robert W. Baird, UBS Group AG, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ACH.

What is the current price target for Accendra Health?

0 Wall Street analysts have set twelve-month price targets for Accendra Health in the last year. Their average twelve-month price target is $5.17, suggesting a possible upside of 76.9%. Robert W. Baird has the highest price target set, predicting ACH will reach $6.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $4.50 for Accendra Health in the next year.
View the latest price targets for ACH.

What is the current consensus analyst rating for Accendra Health?

Accendra Health currently has 1 sell rating, 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACH, but not buy more shares or sell existing shares.
View the latest ratings for ACH.

How do I contact Accendra Health's investor relations team?

Accendra Health's physical mailing address is 10900 NUCKOLS ROAD, GLEN ALLEN, VA 23060. The company's listed phone number is (804) 277-4304 and its investor relations email address is [email protected]. The official website for Accendra Health is www.accendrahealth.com. Learn More about contacing Accendra Health investor relations.